AI risk now arrives inside the ordinary investment-grade sleeve

The corporate bond market has begun pricing AI as its own risk, and that price lands inside ordinary client allocations: AI-related debt now trades at about 115 basis points against roughly 78 for the rest of investment grade, according to AdvisorHub's market brief, while hyperscaler issuance is projected to reach a record $420 billion next year, up 60% from estimated 2026 levels.

AdvisorHub's read is that investors are pricing supply rather than default: technology companies are flooding the market with debt to fund data centers, chips and other infrastructure, and bondholders are answering by demanding higher yields and reconsidering concentration limits. That last item should stop an advisor mid-rebalance. Concentration limits are what a core fixed-income sleeve is made of, and if the largest institutional buyers are reconsidering theirs, the broadest mandates are the accounts left absorbing whatever the pickier ones pass on.

Roughly 37 extra basis points is not an irrational price for that, since a mandate that takes every new line collects the spread and keeps no right of refusal in a year when one theme dominates new supply. The awkward part is where the exposure lands: when the marginal issuer is a data-center financier, an investment-grade fund is making a call on AI capex financing that nobody had to sign off on; the position came with the calendar, not with a decision.

The equity market is pricing the same buildout: Accelevation, backed by Olympus Partners, is targeting a valuation of as much as $5.37 billion in a U.S. IPO and, alongside existing shareholders, plans to raise up to $720 million, while the company designs and installs power distribution, cooling and modular infrastructure for data centers. AdvisorHub treats the offering as a test of whether investors will extend the AI trade past chipmakers and hyperscalers into the physical plant underneath, which is the credit question in equity form: how much of the buildout belongs in a client account, and at what price the market keeps funding it.

The judgment for portfolios is that supply arguments are the ones advisors can underwrite, and a 37-point premium for some of the strongest borrowers in the corporate market is a good price for a buyer who is not compelled to take every line. That favors sleeves where someone can actually decline a deal, and it argues against loading the fixed-income sleeve with the most index-like exposure available. It also means the pain, if it arrives, shows up as total return and refinancing cost before it shows up as credit loss, so a sleeve built only to survive defaults is built for the wrong event.

Demand is the other half: the same AI buildout that is showing up in advisory firms' own technology renewal invoices, as this publication has reported, is funded at the other end by the bond supply now pricing at 115. Watch the calendar rather than the spread: if next year's $420 billion of hyperscaler paper arrives as projected, the 37-point gap is the opening level of a negotiation, and any sleeve without a written concentration rule is a price-taker in it.